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Abstract
Background: We have previously evaluated the vaccine efficacies of seven tetraspanins of Echinococcus multilocularis (Em-
TSP1–7) against alveolar echinococcosis (AE) by subcutaneous (s.c.) administration with Freund’s adjuvant. Over 85% of liver
cyst lesion number reductions (CLNR) were achieved by recombinant Em-TSP1 (rEm-TSP1) and -TSP3 (rEm-TSP3). However,
to develop an efficient and safe human vaccine, the efficacy of TSP mucosal vaccines must be thoroughly evaluated.
Methodology/Principal Findings: rEm-TSP1 and -TSP3 along with nontoxic CpG ODN (CpG oligodeoxynucleotides)
adjuvant were intranasally (i.n.) immunized to BALB/c mice and their vaccine efficacies were evaluated by counting liver
CLNR (experiment I). 37.1% (p,0.05) and 62.1% (p,0.001) of CLNR were achieved by these two proteins, respectively. To
study the protection-associated immune responses induced by rEm-TSP3 via different immunization routes (i.n.
administration with CpG or s.c. immunization with Freund’s adjuvant), the systemic and mucosal antibody responses
were detected by ELISA (experiment II). S.c. and i.n. administration of rEm-TSP3 achieved 81.9% (p,0.001) and 62.8%
(p,0.01) CLNR in the liver, respectively. Both the immunization routes evoked strong serum IgG, IgG1 and IgG2a responses;
i.n. immunization induced significantly higher IgA responses in nasal cavity and intestine compared with s.c. immunization
(p,0.001). Both immunization routes induced extremely strong liver IgA antibody responses (p,0.001). The Th1 and Th2
cell responses were assessed by examining the IgG1/IgG2a ratio at two and three weeks post-immunization. S.c.
immunization resulted in a reduction in the IgG1/IgG2a ratio (Th1 tendency), whereas i.n. immunization caused a shift from
Th1 to Th2. Moreover, immunohistochemistry showed that Em-TSP1 and -TSP3 were extensively located on the surface of E.
multilocularis cysts, protoscoleces and adult worms with additional expression of Em-TSP3 in the inner part of protoscoleces
and oncospheres.
Conclusions: Our study indicated that i.n. administration of rEm-TSP3 with CpG is able to induce both systemic and local
immune responses and thus provides significant protection against AE.
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Introduction
Alveolar echinococcosis (AE), caused by E. multilocularis,i s
known as a very important zoonotic disease, which is endemic in
the large areas of the Northern Hemisphere [1] and is often life-
threatening. E. multilocularis infection of intermediate hosts
(humans and rodents) occurs after oral ingestion of mature
oncosphere-containing eggs. In the small intestine, the onco-
spheres hatch out and then migrate via the hepatic vein to the
liver, where they form cyst masses and increasingly transform into
multiple vesicles filled with fluid and protoscoleces. The parasitic
vesicles are lined with a germinal layer (GL) and a laminated layer
(LL), which are immediately surrounded by an exuberant
granulomatous response generated by the host immune system
[2,3]. Development/infection of E. multilocularis larvae in host
intestine, blood and liver is characterized by systemic and/or
www.plosntds.org 1 March 2012 | Volume 6 | Issue 3 | e1570mucosal immune responses. However, it doesn’t mean that all the
immune responses are protection-associated. To the contrary, some
are modulated by the parasites and are thus susceptibility-
associated. In particular, during the chronic stage of infection,
protective immune responses are down-regulated by Echinococcus
parasites using some molecules for benefiting their long-term
survival in the intermediate host liver [4–7]. Studies of immuno-
logical profiles showed that, in the infected intermediate host, early
Th1-polarized cytokine production, which can kill the metacestodes
at the initial stages of development, shifts to a predominantly Th2
response during the chronic stage [4,6,8]. It is believed that in
Echinococcus infection, Th2 responses are mainly associated with
susceptibility to Echinococcus infection, whereas Th1 responses
contribute to protection [5,6,8–13]. As was shown, some of the
proteins expressedon the surfaceof,orexcretedbycestode parasites
are involved in immunoregulations, whereby the parasites escape
host immune attack and survival in the long term [14–17].
Therefore, suppressing/interfering with the function of these
proteins using specific antibodies or immune-associated cytokines
are key points considerable for efficient vaccine design. Much
progress has been made in vaccine development against Schistosoma
parasite infection using a surface protein, tetraspanin [15–17]. In
our previous study, seven tetraspanins have been identified in E.
multilocularis larvae and are used to develop vaccines against E.
multilocularis infection, which induced significant levels of protection
when subcutaneously administered with Freund’s adjuvant [18].
Remarkably, vaccinations with rEm-TSP1 and -TSP3 were shown
to induce strong serum IgG immune responses in immunized
BALB/c mice and received an .85% of liver cyst lesion number
reductions (CLNR) after orally challenged with parasite eggs.
However, due to the toxicity of Freund’s adjuvant [19,20], an
extensiveapplication ofthisvaccine modelinhumansisnotfeasible.
Of the adjuvants used to develop anti-helminth vaccines, CpG
ODN has been proved an ideal choice for its non-toxicity and ability
enable to induce strong systemic and/or local protective immune
responses [21]. Many studies developing anti-protozoan and -
helminth vaccines used CpG as an adjuvant [22–24]. Evaluation of
the adjuvant efficacy and safety of CpG in primates, including
humans [25,26], made itpossible for developing safe humanvaccines.
CpG was reported to induce strong anti-parasite mucosal
immune responses [22]. Mucosal administration is painless and
easier than other administration routes and able to induce more
specific antibodies, predominantly in local secretions, against
pathogens invasion [27]. Intranasal administration (i.n.), the most
efficient mucosal delivery route for antigens, has the following
properties that make it the priority route in the present study. First,
it is thought to confer the highest level of mucosal immunity, which
is capable of priming a full range of local immune responses (so-
called ‘common mucosal immune system’) as well as systemic
immune responses against protective antigens [28], and only
requires a small antigen dose [29,30]. Second, it does not require
injectionandisthereforesafeand painless.Third,itdoesnotrequire
trained medical personnel for delivery and is thus more appropriate
for mass vaccination programmes, especially in under-developed
countries [27]. To date, i.n. immunization of antigens against
helminth infection has achieved much in Ascaris suum [31,32],
Trichinella spiralis [33], Schistosoma mansoni [34] and E. granulosus [35].
As a pilot study on evaluation of i.n. vaccine efficacy of TSPs,
two independent experiments were performed by us. In experi-
ment I, we compared the i.n. vaccine efficacy between rEm-TSP1
and -TSP3 which showed .85% of liver CLNR in our previous
study, when used as an s.c. vaccine [18]. In experiment II, we
evaluated the vaccine efficacy of rEm-TSP3 plus Freund’s
adjuvant (s.c.) versus rEm-TSP3 plus CpG adjuvant (i.n.) under
the same experimental conditions. The systemic (serum) and local
(nasal cavity, intestine and liver) immune responses induced by
both administration routes were investigated and their possible
roles in protection discussed.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations set out in the Guidelines for Animal Experi-
mentation of the Japanese Association for Laboratory Animal
Science and the protocol for the animal experiments was approved
by the ethics committee of Hokkaido University (Permit Number:
09-0144) and the Hokkaido Institute of Public Health (Permit
Number: K20-6). All surgery was performed under isoflurane
anesthesia, and all efforts were made to minimize suffering.
Cloning and expression of Em-TSP1 and Em-TSP3
The regions encoding the LEL (large extracellular loop) domain
of Em-TSP1 and Em-TSP3 were amplified from the full-length
enriched cDNA library of E. multilocularis metacestode, subcloned
into the pBAD/Thio-TOPO vector (Invitrogen, USA), expressed
and purified as previously described [18]. Briefly, E. coli TOP10
cells (Invitrogen, USA) were transformed with a recombinant
plasmid according to the manufacturer’s instructions (pBAD/
TOPOH ThioFusion
TM Expression Kit, Invitrogen, USA).
Recombinant proteins were purified from E. coli lysates using a
HisTrap affinity column under nondenaturing conditions (Hi-
sTrap FF crude 1 ml, GE Healthcare, USA) and stored at 280uC.
A pBAD/Thio-TOPO vector without inserts was also expressed
and thioredoxin (TRX) was purified as a negative control.
Genbank accession number for tetraspanins used in this study
and those referred in the text were listed in Table S1.
Localization of Em-TSP1 and Em-TSP3 by
immunohistochemistry
Cyst tissue and protoscoleces of Hokkaido isolate were derived
individually from infected Mongolia gerbils and cotton rats. Adult
worms were isolated from the intestine of an infected dog. Samples
Author Summary
Humans and rodents become infected with E. multi-
locularis by oral ingesting of the eggs, which then develop
into cysts in the liver and progress an endless proliferation.
Untreated AE has a fatality rate of .90% in humans.
Tetraspanins have been identified in Schistosoma and
showed potential as the prospective vaccine candidates. In
our recent study, we first identified seven tetraspanins in E.
multilocularis and evaluated their protective efficacies as
vaccines against AE when subcutaneously administered to
BALB/c mice. Mucosal immunization of protective proteins
is able to induce strong local and systemic immune
responses, which might play a crucial role in protecting
humans against E. multilocularis infection via the intestine,
blood and liver. We focused on Em-TSP3, which achieved
significant vaccine efficacy via both s.c. and i.n. routes. The
adjuvanticity of nontoxic CpG OND as i.n. vaccine adjuvant
was evaluated. The widespread expression of Em-TSP3 in
all the developmental stages of E. multilocularis, and the
strong local and systemic immune responses evoked by
i.n. administration of rEm-TSP3 with CpG OND adjuvant
suggest that this study might open the way for developing
efficient, nontoxic human mucosal vaccines against AE.
Mucosal Vaccine against Alveolar Echinococcosis
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Miles, USA) and stored at 280uC. Cryosections (5 mm) were cut
on a Leica CM1900 rotatory microtome (Leica, Germany) at
220uC, mounted on slides, and then fixed in acetone for 10 min.
After air drying, the slides were re-hydrated in phosphate buffered
saline (PBS) and endogenous peroxidase was inactivated by
incubating for 10 min in 0.3% hydrogen peroxide (H2O2) (in
methanol). Samples were washed with PBS for 5 min and
incubated with rabbit anti-rEm-TSP1 and -TSP3 antibodies
respectively, at a dilution of 1:600 in 3% BSA/PBS for 1 h. After
an additional washing step as above, the slices were incubated with
Alexa Fluor R488 goat anti-rabbit IgG (H+L) (Invitrogen, USA) at
a dilution of 1:2,000 in 3% BSA/PBS for 1 h. Following three
washing steps, the stained samples were embedded in glycerol/
phosphate buffer (v/v, 9:1) and viewed under an Olympus BX50
fluorescence microscope (Olympus, Japan). All procedures were
carried out at room temperature. Pre-immune rabbit serum was
used as a negative control.
Mice and parasite eggs
Five-week-old BALB/c mice (male) were maintained in cages in
a P3 animal room at 23–25uC with a 12 h light/12 h dark cycle.
Litter was cleaned weekly. They were provided with food and
water ad libitum and immunized at the age of 6 weeks. E.
multilocularis (Hokkaido isolate) eggs were collected from the feces
of an experimentally-infected dog. Eggs were microscopically
observed to confirm their morphological integrity before challenge
(classical morphology of an egg isolated from the dog is shown in
Figure S1).
Experimental design
Experiment I: Efficacy of i.n. rEm-TSP1 and -TSP3
vaccines. To determine the vaccine efficacy of rEm-TSP1 and
-TSP3 administered i.n., 25 BALB/c mice were divided into five
groups (Table 1). Mice were immunized once per week for 3 weeks
with rEm-TSPs at a dose of 50 mg/animal (diluted in 50 mlP B S )
with adjuvant CpG ODN (1 nM/mouse) (Hokkaido System
Science, Japan). CpG ODN containing unmethylated CpG motifs
acts as immune adjuvant in mice, boosting the humoral and cellular
response to coadministered antigens. One week after the final
immunization, mice were anesthetized and challenged orally with
0.5 ml E. multilocularis eggs (400 eggs/ml in physiological saline)
collected from the feces of an experimentally-infected dog. One
month post-infection, all mice were sacrificed and necropsies
performed for counting the number of cyst lesions (Figure S2).
Experiment II: Efficacy of the s.c.- and i.n.-administered
rEm-TSP3 vaccine and associated immune responses. 1.
S.c. and i.n. administration. To confirm the vaccine efficacies
of rEm-TSP3 delivered via the i.n. and s.c. administration routes
and to examine the protection-associated immune responses, 72
BALB/c mice were grouped as shown in Table 2. The
recombinant protein, rEm-TSP3 (which produced the highest
reduction in the number of cyst lesions in experiment I) was weekly
immunized to BALB/c mice at a dose of 50 mg/mouse (in 50 ml
PBS) plus CpG adjuvant (1 nM/mouse) (i.n.) or Freund’s complete
adjuvant (CFA, MP Biomedicals, USA) and Freund’s incomplete
adjuvant (IFA, MP Biomedicals, USA) (s.c.) for three times.
Freund’s adjuvant was used at a dose of 50 ml per mouse
individually to minimize the suffering to mice (http://oacu.od.nih.
gov/ARAC/documents/Adjuvants.pdf). After the last immuniza-
tion, blood was collected from the mice orbits using glass capillary
pipettes (Hirschmann, Germany) and the serum was separated.
Three out of eight mice from each group were sacrificed, and the
nasal cavity washes, intestines and liver were collected. Samples
were stored at 220uC. Challenge with parasite eggs and the
procedures used to count the number of cyst lesions in the
remaining mice were conducted as described in experiment I.
2. ELISA (enzyme linked-immunosorbent assay)
determination of antibody responses. To evaluate the IgG
(including IgG1 and IgG2a subclasses), IgA and IgM antibody
responsesinbloodinduced byvaccinationviathetwoadministration
routes used in experiment II, bloods were collected and sera
separated. To evaluate IgA antibody responses in the local mucosal,
nasal cavity washes were collected in 500 mlo fP B S( p H7 . 4 )a n d
insoluble debris removed by centrifugation. A 10-cm fragment of the
ileal region of the intestine was excised and the intestinal tube was
opened using scissors and immersed in 250 mlo fP B S .L i v e r sw e r e
homogenized in 500 ml of PBS and extracts were obtained by
centrifugation. Samples were vigorously vortexed and centrifuged to
collect the supernatants. Indirect ELISA was performed for the
antibody analysis as previously described [18]. Briefly, 96-well
microtiter plates(Corning,USA) were coated with rEm-TSP1/rEm-
TSP3 proteins (0.25 mg/well), blocked with 5% skim milk. To detect
serum IgG, IgG1, IgG2a, IgA and IgM, plates were incubated with
sera at a dilution of 1:2,000 followed by incubation with horseradish
peroxidase (HRP)-conjugated anti-mouse IgG (Invitrogen, USA),
IgG1 (Rockland, USA), IgG2a (SouthernBiotech, USA), IgA
(Invitrogen, USA) or IgM (MP Biomedicals, USA). To detect IgA
responses in nasal cavity, intestine and liver, plates were incubated
with the nasal cavity washes, intestine washes and liver extracts at a
dilution of 1:10, respectively, followed by incubation with HRP-
conjugated anti-mouse IgA (Invitrogen, USA). Color reactions were
developed by addition of 100 mlo fT M B( 3 ,3 9,5 ,5 9-
tetramethylbenzidine) substrate (Dojindo, Japan). Absorbance was
measured at 450 nm in a Biotrak II plate reader (Amersham
Biosciences, USA). Antisera were pre-absorbed with purified TRX
to deplete antibodies directed to the fusion partner protein TRX.
3. Determination of complement-mediated lysis of
protoscoleces in vitro. Sera from rEm-TSP3-immunized and
-non-immunized mice were collected after the third immunization.
Protoscoleces were obtained from a cotton rat orally infected with
eggs 6 months at the Hokkaido Institute of Public Health. The
number of protoscoleces was adjusted to 1,000/ml in PBS and
0.025 ml (about 25 protoscoleces) was added to a concave slide.
Untreated/normal serum and serum incubated at 56uC for
30 min (complement inactivation) were used to confirm the lytic
effect of complement. To identify the complement activation
pathway involved, sera were incubated at 50uC for 30 min to
inactivate C3 proactivator. Sera (0.05 ml) were added to the
prepared protoscoleces on the concave slide and mixed before a
cover slip was applied. Concave slides were incubated at 37uC and
protoscolex lysis was observed under light microscope after 0.5, 1,
2 and 8 h.
Table 1. Intranasal vaccination groups used for experimental
I.
Group
Protein (50 mg/
mouse) Number of mice Eggs for challenge
1 PBS 5 200
2P B S +CpG 5 200
3 TRX+CpG 5 200
4 rEm-TSP1+CpG 5 200
5 rEm-TSP3+CpG 5 200
doi:10.1371/journal.pntd.0001570.t001
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vaccine. One month post-infection, all mice were sacrificed and
necropsies performed. Livers were collected in plastic dishes and
stored at 4uC overnight to harden them before they were cut into
approximately 0.5-mm thick slices (Figure S2). All detectable
lesions were counted and the protection rate (percentage reduction
in the cyst lesions of experimental groups compared with that in
the PBS control) was calculated using the formula:
PR~CLRR~
CLNC-CLNE
CLNC
|100%
where PR=protection rate, CLRR=cyst lesion reduction rate,
CLNC=cyst lesion number from control group, CLNE=cyst
lesion number from experimental group.
Statistical analyses
The data were analyzed using one-way ANOVA followed by a
multiple comparison Tukey’s test. Differences were considered
statistically significant at p,0.05, very significant at p,0.01 and
extremely significant at p,0.001.
Results
Immunolocalization of Em-TSP1 and Em-TSP3 in larval
and adult E. multilocularis
Staining revealed immunolocalization of Em-TSP1 and Em-
TSP3 at the surface (germinal layer/tegument) of both forms of E.
multilocularis larva (cyst and protoscolex) (Figure 1A,B) and both of
the antigens were also detected on the tegument of the adult
worms (Figure 1C). Interestingly, expression of Em-TSP3 was also
detected on the sucker and rostellum of the protoscoleces
(Figure 1B) and on the oncospheres in adult eggs (Figure 1C,D).
Pre-immunized serum, used as a negative control, had no obvious
reaction with any of the fixed tissues (Figure 1). Microscopic
images of H&E-stained larvae, adults and eggs are also shown as a
reference (Figure 1).
Determination of rEm-TSP1 and -TSP3 vaccine efficacies
after i.n. administration
In experiment I, vaccination of mice with rEm-TSP3 plus CpG
significantly reduced the liver cyst lesion numbers (62.1%,
p,0.001), compared with that in the PBS control group. The
liver CLNR after immunization with rEm-TSP1 plus CpG was
significant (p,0.01), but lower (37.1%) than that after immuniza-
tion with rEm-TSP3. A mixture of rEm-TSP1 and -TSP3 also
resulted in a significant, but lower (28.7%, p,0.05), rate of liver
CLNR than either rEm-TSP1 or rEm-TSP3. The CLNRs in the
CpG and TRX control groups were 10.9% and 22.1% (p.0.05),
respectively (Table 3). The difference in the vaccine efficacy
between rEm-TSP1 and -TSP3 was statistically significant
(p,0.05).
Vaccine efficacies of rEm-TSP3 administered via different
routes
In experiment II, s.c. immunization with rEm-TSP3 signifi-
cantly reduced the number of cyst lesions (82%, p,0.001)
compared with that in the control group. The liver CLNR in
the TRX and CpG control groups were 44% (p,0.05) and 27%
(p,0.05), respectively. I.n. immunization with rEm-TSP3 plus
CpG resulted in a CLNR of 61% (p,0.01), whereas rEm-TSP3
alone, and the TRX and CpG controls showed reductions of 22%
(p.0.05), 38% (p,0.05) and 37% (p,0.05), respectively (Table 4).
There was a significant difference between the vaccine efficacies of
the two administration routes (p,0.05).
Antibody response in mice immunized s.c. and i.n. with
rEm-TSP3
Antibody responses against rEm-TSP3 evoked by s.c. and i.n.
administration were detected by ELISA. Compared with the
PBS control, significant IgG responses were detected in the
groups immunized with rEm-TSP3+CFA/IFA (p,0.001) and
rEm-TSP3+CpG (p,0.001) (Figure 2A). A significant difference
was observed between the two administration routes (p,0.001).
In the i.n. group, a significant difference was observed between
rEm-TSP3+CpG and rEm-TSP3 (p,0.001) alone. Strong IgG1
and IgG2a subclass antibody responses were induced by both s.c.
and i.n. administration of rEm-TSP3 with adjuvants (p,0.001),
while rEm-TSP3 alone induced neither significant IgG1 nor
IgG2a responses (Figure 2B,C). Significant IgM antibody
responses were detected in both s.c. (p,0.001) and i.n.
(p,0.05) groups immunized with rEm-TSP3 plus adjuvant, but
there was no significant difference observed between them. rEm-
TSP3 alone did not induce a significant IgM antibody response
Table 2. Subcutaneous and intranasal vaccination groups in experiment II.
Group (s.c.) Protein (50 mg/mouse) Number of mice Eggs for challenge
1 PBS 8 200
2 PBS+CFA/IFA 8 200
3T R X +CFA/IFA 8 200
4 rEm-TSP3+CFA/IFA 8 200
Group (i.n.) Protein (50 mg/mouse) Number of mice Eggs for challenge
5 PBS 8 200
6 PBS+CpG 8 200
7T R X +CpG 8 200
8 rEm-TSP3 8 200
9 rEm-TSP3+CpG 8 200
s.c.=subcutaneous;
i.n.=intranasal.
doi:10.1371/journal.pntd.0001570.t002
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detected in the group immunized with rEm-TSP3+CpG
(p,0.001) (Figure 2E).
In the nasal cavity, an extremely high IgA response (p,0.001)
was only detected in the group i.n. immunized with rEm-
TSP3+CpG (Figure 3A). I.n. immunization with rEm-TSP3+CpG
induced higher intestinal IgA responses (p,0.001) than the other
groups (Figure 3B). In the liver extracts, significant IgA responses
were detected in the groups immunized with rEm-TSP3+CFA/
IFA (s.c.) (p,0.001) and rEm-TSP3+CpG (i.n.) (p,0.01), with the
former being slightly higher (Figure 3C).
Th1 and Th2 cell responses were assessed according to the
IgG1/IgG2a ratio (Table 5). Two weeks post-immunization, s.c.
immunization induced a mixed Th1/Th2 response, with the Th2
response predominating. This shifted to a reduced IgG1/IgG2a
ratio 3 weeks post-immunization (a Th1 tendency). Inversely, i.n.
Figure 1. Immunolocalization of Em-TSP1 and Em-TSP3 on the larval and adult stages of E. multilocularis. Polyclonal rabbit thioredoxin-
absorbed anti-Em-TSP1 and anti-Em-TSP3 antibodies, pre-immunized sera (negative controls), and Alexa Fluor R488 goat-anti-rabbit IgG (H+L) were
used in the experiment. Parasites were frozen in Tissur-Tek O.C.T. Compound and cryosections were cut for immunohistochemistry. Localization of
Em-TSP1 and Em-TSP3 in cysts (A), protoscoleces (B), adult worms (C) and eggs (D). The scale of microscopy images is shown on the lower right of
each slice (scale bar=100 mm in (A)–(C) and 25 mm in (D)). Fluorescence-labeled Em-TSP1 and Em-TSP3 on the surface of cysts, protoscoleces and
adults are indicated by the red arrows. Expression of Em-TSP3 on the sucker and rostellum of the protoscoleces and on the oncospheres of eggs is
indicated by the blue arrows. Pre-immunized serum (negative control) had no obvious reaction with any of fixed tissue sections. Microscopic images
of HE-stained larvae, adults and eggs are shown as a reference. GL=geminal layer; PSC=protoscolex; HT=host tissue; T=tegument; R=rostellum;
S=sucker; E=egg; O=oncosphere; and M=membrane.
doi:10.1371/journal.pntd.0001570.g001
Table 3. Cyst lesion numbers and reductions achieved in
experiment I.
Group CLN CLNR CLRR (%)
Range Mean
1 (PBS) 67–96 76.0 0 0
2 (PBS+CpG) 55–77 67.7 8.3 10.9
3 (TRX+CpG) 49–67 59.2 16.8 22.1
4 (rEm-TSP1+CpG) 36–58 47.8 28.2 37.1
5 (rEm-TSP3+CpG) 19–44 28.8 47.2 62.1
CLN=Cyst lesion number;
CLNR=Cyst lesion number reduction;
CLRR=Cyst lesion reduction rate.
doi:10.1371/journal.pntd.0001570.t003
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response to Th2-dominant one.
Complement-mediated lysis of protoscoleces
Complement-mediated lysis of protoscoleces began 2 h after the
addition of untreated sera (from both non-immunized and
immunized groups) and most were lysed at 8 h (Figure 4A,D);
however, no lysis of protoscoleces treated with complement-
inactivated sera (Figure 4B,E) was observed. Also, there was no
visible protoscolex lysis after inactivation of C3 proactivator at
50uC for 30 min (Figure 4C,F).
Discussion
As a transmembrane protein, tetraspanin is abundantly
expressed on the tegument or body wall of some helminthes,
including Schistosoma mansoni [15,36], S. japonicum [16] and
Caenorhabditis elegans [37], and is believed to play very important
roles in signal transduction, cell proliferation, adhesion, migration,
fusion and host-parasite interactions [38,39]. Recently, we cloned
seven tetraspanins (Em-TSP1–7) from E. multilocularis [18], of
which only Em-TSP5 (E24) was confirmed its location on the
surface of the larvae (cysts and protoscoleces) [40]. In this study,
immunohistochemical analysis showed that both Em-TSP1 and -
TSP3 are expressed on the surface of larvae and adult worms.
Notably, the expression of Em-TSP3 on sucker, rostellum and
inner tegument of protoscoleces and oncospheres was also
observed. From these results we proposed that these proteins play
important roles in Echinococcus-host interactions and that using
them as vaccines may interfere with the parasite survival strategy
[15,17,41–44]. Moreover, as reported previously, tetraspanins
showed their potential protective effects against different stages of
Schistosoma infections [15,41–43]. Thus, vaccination of Em-TSP1
and -TSP3 proteins is believed to provide ‘broad-spectrum
protection’ against the different stages infection by E. multilocularis.
We previously showed the high protective efficacy of seven
tetraspanins (TSP1–7) against E. multilocularis infection in BALB/c
mice after s.c. administration with Freund’s adjuvant [18].
However, the toxicity of Freund’s adjuvant limits the application
of this vaccine model to human vaccines [19,20]. Therefore, in this
study, we used nontoxic CpG ODN as a vaccine adjuvant, which
induces both systemic and mucosal immune responses in
immunized animals [21], and evokes strong protective immune
responses when used as mucosal adjuvant [22,25,45–47]. Studies
on evaluation of CpG adjuvant efficient in primates (including
humans) undoubtedly is an important step in human mucosal
vaccine development [25,26]. Recently, CpG was used as a
mucosal adjuvant in developing anti-protozoan and -helminth
vaccines [22–24]. Of the different mucosal administration routes,
i.n. delivery is the most appropriate, mainly because it induces the
full range of local immune responses (so-called ‘common mucosal
immune system’) [28] and induces strong immunity after only
small dose of vaccine [29,30].
Based on the above properties, i.n. immunization and the CpG
adjuvant has many advantages; therefore, we evaluated the
efficacy of i.n. delivery of the rEm-TSP1 and -TSP3 vaccines
using CpG as an adjuvant, and further investigated the systemic
and mucosal immune responses mounted against rEm-TSP3,
compared with those induced by s.c. immunization using Freund’s
adjuvant.
In experiment I, significantly high liver CLNRs, resulted from
i.n. immunization with rEm-TSP1 plus CpG (37.1%, p,0.01) and
rEm-TSP3 plus CpG (62.1%, p,0.001), were observed compared
with the PBS control. However, our previous study reported the
efficacies of 87.9% and 85.1%, respectively, for the rEm-TSP1
and -TSP3 vaccines, when administered s.c. with Freund’s
adjuvant [18]. Taken together, our own results and those of
others [48], conclude that different antigen delivery routes greatly
affect vaccine efficacy.
In experiment II, we focused on the rEm-TSP3 protein, which
showed higher liver CLNR than rEm-TSP1 in experiment I. We
investigated systemic and mucosal immune responses associated
with protection in BALB/c mice immunized s.c. or i.n. Under the
same conditions, the vaccine efficacies induced by the two
immunization routes were similar to those observed in Experiment
I and our previous study [18]. ELISA data showed that, after the
third immunization, extremely significant serum IgG immune
responses were induced by both the administration routes
(p,0.001), with the former stronger than the latter (p,0.001).
Meanwhile, significant levels of IgG1, IgG2a and IgM antibodies
were detected. Th1 and Th2 cell responses were evaluated
according to the IgG1/IgG2a ratio. After the second immuniza-
tion, a mixed Th1/Th2 cell response was evoked in the s.c.-
immunized group, dominated by a Th2 response, whereas the
IgG1/IgG2a ratio reduced after the third immunization (a Th1
tendency). Inversely, i.n. immunization resulted in a shift from a
Th1 to a Th2 response. As previously reported, antibodies form a
critical part of the immune response against taeniid metacestodes,
with IgG1, IgG2a, IgG2b, and IgE play a major role in
oncosphere killing, although the involvement of other mechanisms
can not be ruled out [4]. Antibody-dependent, complement-
mediated lysis is a pivotal characteristic during the early stages of
taeniid cestodes infection of intermediate hosts [4,49]. Interest-
ingly, our in vitro complement assay showed the lytic effect on
protoscoleces by both normal/non-immunized and rEm-TSP3-
immunized serum from BALB/c mice. Notably, treatment of sera
at 56uC for 30 min (complement inactivation) or at 50uC for
30 min (C3 proactivator inactivation) abolished protoscolex lysis,
suggesting that at least an alternative pathway exists in BALB/c
mice for complement activation in the initial infection of
Echinococcus metacestode.
Growing evidences suggest the importance of a Th1/Th2
balance during parasite infections, such as infections by Trypano-
soma [50], Schistosoma [15,17] and Echinococcus [4–8,10–13]. In
Table 4. Cyst lesion numbers and reductions achieved in
experiment II.
Groups CLN CLNR CLRR (%)
Range Mean
1 (PBS) 47–74 56.4 0 0
2 (PBS+adj.) 29–50 41.0 15.4 27.3
3 (TRX+adj.) 11–58 31.6 24.8 44.0
4 (rEm-TSP3+adj.) 4–19 10.2 46.2 81.9
5 (PBS) 46–78 54.2 0 0
6 (PBS+CpG) 26–39 34.0 20.2 37.3
7 (TRX+CpG) 16–47 33.8 20.4 37.7
8 (rEm-TSP3) 29–62 42.2 12.0 22.1
9 (rEm-TSP3+CpG) 9–29 21.0 33.2 61.3
adj.=CFA/IFA adjuvant;
CLN=Cyst lesions number;
CLNR=Cyst lesion number reduction;
CLRR=Cyst lesion reduction rate.
doi:10.1371/journal.pntd.0001570.t004
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which can kill the metacestodes at the initial stages of
development, shifts to a Th2 cytokine response during the chronic
stage [4,6,8]. The characteristic of Th1 profile, mainly induced by
IL-12, is the secretion of IL-2, TNF and especially IFN-c, which
lead to the recruitment and activation of the cellular effector phase
of immunity [51,52]. A shift from a Th1 to a Th2 cytokine profile,
mainly induced by an increased secretion of IL-10, a cytokine
typically associated with immunoregulation of effector responses, is
thought to limit and ultimately terminate inflammatory responses
[53–55].
Echinococcus metacestode has developed a number of strategies
for escaping host immune attack [4–7]. The shift from a protective
immune response (Th1 response) to a nonprotective one (Th2
response) is thought to be one of the most important mechanisms,
whereby Echinococcus metacestodes regulate host immune responses
to benefit their long-term survival in the hosts, by using some
molecules like antigen B [56]. Tetraspanins in the tegument of
schistosomula and adult worms are suggested to act as receptors
for host ligands, including MHC molecules, by which parasites
mask their nonself status, and thereby escape host immune
responses [15]. In the present study, because CpG was expected to
(but actually failed to) elicit significant Th1 cell responses as
previously reported [21], we hypothesize that the tetraspanins used
also share the same immunomodulatory mechanism as antigen B.
This would offset of the adjuvant activity of CpG (and even
Freund’s adjuvant), which would provide a reasonable explanation
for the induction of predominant Th2 cell responses in this study.
It is clear that systemic immune responses, as mentioned above,
play a crucial role in protection against Echinococcus parasite
infections. However, since the early, natural infection of eggs/
oncospheres begins at the gastrointestinal membrane and the
invasion, rooting and development/proliferation of Echinococcus
metacestodes occurs in the host organs (mainly the liver), the
immunological events occurring at the local mucosa should not be
neglected.
Secretory IgA is a critical component of the mucosal immune
system and plays an important role as the first lines of defense
Figure 2. Serum antibody responses in BALB/c mice immunized with rEm-TSP3 either subcutaneously or intranasally. BALB/c mice
were immunized with recombinant Em-TSP3 at a dose of 50 mg/mouse plus adjuvant (CpG for the intranasal group or Freund’s complete adjuvant
(CFA) or Freund’s incomplete adjuvant (IFA) for the subcutaneous group). After the third immunization, blood was collected and sera IgG (A), IgG1 (B),
IgG2a (C), IgM (D) and IgA (E) were assayed by ELISA. Results represent the mean absorbance measured at 450 nm for each group. Significant
differences between the vaccinated groups and the PBS control group are denoted by an asterisk over the bar. Significant differences between any of
the groups are denoted by an asterisk over the line connecting them. n=8 per group; s.c.=subcutaneous; i.n.=intranasal; adj.=adjuvant IFA/CFA.
*p,0.05 (significant); **p,0.01 (very significant); ***p,0.001 (extremely significant).
doi:10.1371/journal.pntd.0001570.g002
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Echinococcus [59]. IgA responses in the mucosa might be
hypothesized to target the parasite by neutralizing parasite
ES products, attenuating the parasite-host interaction and
interfering with parasite feeding and survival [60–62]. Induc-
tion of eosinophil degranulation by IgA is another important
characteristic of mucosal immunol o g i c a le v e n t sa so b s e r v e db y
Abu-Ghazaleh et al. [63]. Additionally, mucosal immunity
could play a role in tolerance induction against E. multilocularis
that may be a prerequisite for the subsequent development of
t h el a r v a ei nt h el i v e r ,a n df o rt h eo c c u r r e n c eo fa l v e o l a r
proliferation [59].
In the present study, a remarkably strong intranasal IgA
response was induced (p,0.001) even though only a very low
level of serum IgA was induced, by i.n. immunization with
rEm-TSP3 plus CpG; however, only a limited intestinal IgA
response was detected. rEm-TSP3 alone (without any adjuvant)
failed to induce a high IgA response in either i.n.-or s.c.-
immunized groups. It is noteworthy that high levels of IgA
antibodies were detected in liver extracts after immunization by
both immunization routes. Although the exact mechanisms
underlying IgA anti-parasite response in the liver are unknown,
infection of this organ by E. multilocularis larvae is characterized
by a chronic process; antibody responses in the liver, including
IgA, as well as other immune-associated factors should not be
neglected [6,64,65] and further studies regarding their roles are
required.
Taken together, the results of the present study suggest that i.n.
administration of rEm-TSP3 plus CpG, which induces systemic
and local immune responses, is a prospective model for the
development of nontoxic human vaccines. It is also proposed that,
in our vaccine model, protection is mainly provided by serum
antibodies including antibody-dependent, complement-mediated
lysis against early infection by E. multilocularis (oncospheres in
blood). Although intestinal IgA is believed to play an important
role in inhibiting invasion of hatched oncospheres, our vaccines
Figure 3. Local mucosal IgA responses induced in mice immunized with rEm-TSP3 either subcutaneously or intranasally. Three out of
eight mice from each group were sacrificed and nasal washes, liver extracts and intestinal washes were collected for measurement of nasal IgA
responses (A), intestinal IgA responses (B) and liver IgA responses (C) by ELISA. Significant differences between the vaccinated groups and the PBS
control group are denoted by an asterisk over the bar. Significant differences between any of the groups are denoted by an asterisk over the line
connecting them. n=3 per group; s.c.=subcutaneous; i.n.=intranasal; adj.=adjuvant IFA/CFA. *p,0.05 (significant); **p,0.01 (very significant);
***p,0.001 (extremely significant).
doi:10.1371/journal.pntd.0001570.g003
Table 5. IgG1 and IgG2a antibody profiles post-s.c. and -i.n. vaccination with rEm-TSP3.
Administration routes Groups
IgG1 IgG2a IgG1/IgG2a
rEm-TSP3 PBS rEm-TSP3 PBS rEm-TSP3
s.c. 2 weeks p.i. 0.82760.455 0.06060.003 0.45760.251 0.07160.007 1.81
3 weeks p.i. 1.29760.124* 0.06160.003 1.09360.274* 0.07060.004 1.19
i.n 2 weeks p.i. 0.34460.098 0.06560.019 0.43260.148 0.07160.005 0.80
. 3 weeks p.i. 1.01460.233* 0.07060.014 0.83460.201* 0.06860.003 1.22
s.c.=subcutaneous;
i.n.=intranasal;
p.i.=post-immunization;
*Statistically significant compared with PBS control group (p,0.05).
doi:10.1371/journal.pntd.0001570.t005
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important consideration in our further work. Moreover, the
extensive expression of Em-TSP3 on the surface/tegument of E.
multilocularis at different developmental stages suggests the
possibility of developing TSP-based vaccines with ‘broad-spectrum
protection’ against the worm infections at different stages
(oncosphere, cyst, protoscolex and even adult). On the other
hand, the surface/tegument tetraspanin proteins may have crucial
functions in protecting the Echinococcus parasite by shifting the host
protective immune response (Th1 response) to non-protective one
(Th2 response), especially during the stages of liver infection.
Therefore, further work is needed to develop new strategies for
offsetting this ‘undesired effect’ of tetraspanin proteins, such as
enhancement of the biological activity of the CpG ODN adjuvant
by modifying its backbone chemistry, and the use of different
delivery methods, including mixing or cross-linking of CpG ODN
to other carrier compounds as reviewed by Mutwiri et al.,
elsewhere [66].
Supporting Information
Figure S1 Classical morphology of an egg from the feces
of an experimentally-infected dog. E=embryophore;
O=oncosphere; H=hook.
(TIF)
Figure S2 Cyst lesions formed by E. multilocularis
larvae in BALB/c mice liver. Immunized mice were
anesthetized and challenged orally with 200 E. multilocularis eggs.
One month post-infection, all mice were sacrificed and the livers
were collected and cut into slices to count the number of cyst
lesions. Cysts are marked in blue circles.
(TIF)
Table S1 List of Genbank accession numbers for the
genes referred to in the text.
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immunized and rEm-TSP3-immunized BALB/c mice. (B) and (E), complement-inactivated sera (56uC for 30 min) did not lyse the protoscoleces. (C) and
(F), no protoscolex lysis was evident after C3 proactivator in the serum was inactivated (50uC for 30 min). Lysed protoscoleces are indicated by a red
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